stronger antiglycation activity than
aminoguanidine, a hydrazine-like compound
that blocks the formation of advanced
glycation end-products (AGEs) (p = 0.001),
as shown in Fig 1, but is not statistically
different from that of the standard
OxyResvenox (p = 1.000).